Phacolytic glaucoma that with most cases, of phacolytic glaucoma post surgery patients are not exposed to many further obstacles in the healing process which therefore avoids the need for medication. Although, it is mostly encouraged that patients take antiglaucoma medication in order to deter the possibility of glaucoma and inflammation implicating the eye. One of these medications include eye drops which contain prostaglandin analogs. Prostaglandin analogs aim to lower intraocular pressure which thereby avoids inflammation to ensure an efficient healing process after cataract removal. Carbonic anhydrase inhibitors (CAI) in the form of pills, disables the production of the sodium pump in the
Minimally invasive glaucoma surgery to augment outflow to the suprachoroidal space in order to control intraocular pressure; it is indicated for the treatment of primary open-angle glaucoma. The stent is implanted through an ab interno approach and inserted into the supraciliary space (between the ciliary body and sclera), effectively creating a controlled cyclodialysis cleft, which is kept open by the device. The first clinical data on the device was presented in 2010 showed sustained IOP lowering and MIGS-like safety profile. This has been substantiated in subsequent studies in the combined setting with cataract surgery and as a stand-alone treatment for patients failing glaucoma topical